Semaglutide is significantly better than Exenatide at both glucose control and decreasing body fat mass. Semaglutide is doing two things at once. This has absolutely no relevance to comparing one allogeneic CAR T to another. For an oncology example, it's like having an anti-cancer drug that synergises with established therapies while also protecting healthy cells of the body. This drug is doing two things at once.
IMU Price at posting:
3.8¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)